Actos (Pioglitazone) Cost in Iowa: 2026 Prices, Medicaid, Insurance & Savings

What Does Generic Pioglitazone Cost at Iowa Pharmacies in 2026?

A 30-day supply of generic pioglitazone tablets costs approximately $15 at Iowa retail pharmacies as of 2026, making it one of the least expensive oral diabetes medications on the market. The branded version, Actos (manufactured by Takeda), carries a list price near $60 per month, but very few pharmacies still dispense the brand when generics are available.

Pioglitazone lost patent exclusivity in 2012, and competition among generic manufacturers has driven prices steadily downward. The $15 average reflects cash-pay pricing without insurance or coupons at chains like Hy-Vee, Walgreens, CVS, and Walmart locations across Iowa. Prices can fluctuate by $3 to $8 between pharmacies in the same city. Walmart and Costco pharmacies in Des Moines, Cedar Rapids, and Davenport tend to sit at the lower end of that range.

For patients paying out of pocket, pioglitazone is notably cheaper than most branded GLP-1 receptor agonists and SGLT2 inhibitors. A month of semaglutide (Ozempic) runs over $900 without insurance, while empagliflozin (Jardiance) lists above $500 per month 1. That cost gap matters. In the PROactive trial (N=5,238), pioglitazone reduced the composite of all-cause mortality, non-fatal MI, and stroke by 16% in patients with type 2 diabetes and macrovascular disease, suggesting cardiovascular benefits that overlap with some of those more expensive drug classes.

Patients who need the 45 mg strength may see slightly higher prices (roughly $18 to $22 per month cash), while the 15 mg tablet often prices below $12.

Does Iowa Medicaid Cover Pioglitazone?

Iowa Medicaid does not cover pioglitazone as of 2026. Patients enrolled in Iowa's Medicaid managed care plans (administered through Amerigroup Iowa and Iowa Total Care) will find pioglitazone absent from the preferred drug list.

This exclusion is not unique to Iowa. Several state Medicaid programs have dropped thiazolidinediones from preferred formularies over the past decade, citing concerns about fluid retention and heart failure risk that emerged from the FDA's 2007 boxed warning and subsequent safety reviews [2]. The American Diabetes Association's 2024 Standards of Care still lists pioglitazone as a second-line option for type 2 diabetes, particularly when insulin sensitization is the clinical goal, but formulary committees weigh population-level risk against per-member cost.

Iowa Medicaid patients who need pioglitazone specifically (for example, those with biopsy-confirmed NASH/MASLD) can request a prior authorization through their prescribing provider. Approval rates for these exceptions are low but not zero. A letter from a hepatologist or endocrinologist citing the PIVENS trial data (discussed below) strengthens the case.

For patients who cannot get Medicaid approval, the $15 cash price is often cheaper than the administrative cost of appealing. That calculation shifts the practical question from "Will Medicaid cover it?" to "Is $15 per month worth the time saved by skipping the appeal?"

How Iowa Insurance Plans Handle Pioglitazone

Commercial insurance plans in Iowa generally cover generic pioglitazone, though tier placement and copays vary. Most major carriers operating in the state, including Wellmark Blue Cross Blue Shield, UnitedHealthcare, and Medica, place generic pioglitazone on Tier 1 or Tier 2.

A Tier 1 copay in Iowa typically runs $5 to $15 per 30-day fill. At that level, the insured price is comparable to or even higher than the $15 cash price, which creates an odd incentive structure. Patients with high-deductible health plans (HDHPs) pay the full cash price until they meet their deductible anyway, so using a GoodRx or RxSaver discount coupon at the pharmacy counter may cost less than running the claim through insurance.

Iowa's ACA marketplace plans, sold through Healthcare.gov, are required to cover at least one drug in each pharmacologic class. Because metformin, sulfonylureas, and thiazolidinediones are separate classes, pioglitazone or a therapeutic equivalent should appear on every qualified health plan formulary. In practice, some plans list pioglitazone with a prior authorization requirement or step-therapy protocol that mandates metformin first.

Medicare Part D plans in Iowa show more variation. The 2026 Inflation Reduction Act provisions cap out-of-pocket spending for Part D enrollees at $2,000 per year across all covered drugs. For a medication as inexpensive as generic pioglitazone, this cap rarely comes into play, but it does provide a ceiling for patients on multiple branded medications who add pioglitazone to their regimen.

Compounded Pioglitazone in Iowa: Legal Status and Practical Access

Compounded pioglitazone is available in Iowa through licensed 503A compounding pharmacies. These pharmacies operate under state Board of Pharmacy oversight and federal guidelines established by the Drug Quality and Security Act of 2013.

A 503A pharmacy compounds medications pursuant to a valid individual prescription. Iowa's Board of Pharmacy permits 503A compounding of pioglitazone provided the pharmacy holds an active Iowa compounding license, the prescription comes from a licensed prescriber, and the compounded product is not essentially a copy of a commercially available drug in the same strength and dosage form.

That last condition is the practical sticking point. Because generic pioglitazone tablets (15 mg, 30 mg, 45 mg) are commercially available and inexpensive, a 503A pharmacy would need clinical justification to compound an equivalent oral formulation. Valid reasons include: a patient with a documented allergy to an inactive ingredient in all commercially available generics, a need for a non-standard dose (such as 7.5 mg or 22.5 mg), or a requirement for an alternative dosage form like a suspension for patients who cannot swallow tablets.

Iowa does not have any 503B outsourcing facilities currently registered with the FDA that list pioglitazone in their product catalogs, so bulk compounding without individual prescriptions is not available in-state. Patients can, however, receive compounded pioglitazone shipped from out-of-state 503B facilities that hold proper interstate distribution licenses.

The practical cost of compounded pioglitazone varies. Some 503A pharmacies absorb the compounding fee for simple formulations, bringing the cost near zero for the active ingredient itself. Others charge $20 to $40 per month for custom preparations. Given that commercial generic pioglitazone costs $15, compounding only makes financial sense when the clinical need genuinely requires a non-standard formulation.

Pioglitazone for NASH/MASLD: The Clinical Case and Iowa Access

Pioglitazone's off-label use in non-alcoholic steatohepatitis (NASH, now termed MASLD) is one of the strongest reasons patients seek this drug specifically rather than another diabetes medication. The evidence base is anchored by the PIVENS trial (Pioglitazone versus Vitamin E versus Placebo for the Treatment of Non-diabetic Patients with Non-alcoholic Steatohepatitis), published in the New England Journal of Medicine in 2010.

PIVENS enrolled 247 adults without diabetes who had biopsy-confirmed NASH. Patients received pioglitazone 30 mg daily, vitamin E 800 IU daily, or placebo for 96 weeks. Pioglitazone improved the histologic NASH activity score in 34% of patients versus 19% on placebo (P=0.04). Vitamin E performed slightly better at 43% (P=0.001 vs. placebo), but pioglitazone was the only agent that also significantly improved insulin resistance and hepatic steatosis on imaging [3].

The AASLD 2023 Practice Guidance for MASLD recommends pioglitazone for patients with biopsy-confirmed NASH regardless of diabetes status, noting: "Pioglitazone improves liver histology in patients with and without type 2 diabetes mellitus with biopsy-proven NASH." This recommendation carries a conditional strength, reflecting moderate-quality evidence.

Dr. Arun Sanyal, a hepatologist at Virginia Commonwealth University who served as lead investigator on PIVENS, has stated: "Pioglitazone remains the only oral medication with randomized controlled trial evidence showing histologic improvement in NASH across both diabetic and non-diabetic populations."

In Iowa, accessing pioglitazone for NASH requires an off-label prescription. Iowa law does not restrict off-label prescribing when supported by peer-reviewed evidence. The barrier is insurance coverage: many Iowa payers will not approve pioglitazone for a hepatology indication without prior authorization, and some deny it outright because NASH is not an FDA-approved indication. Again, the $15 cash price makes out-of-pocket payment a straightforward alternative.

Telehealth Prescribing of Pioglitazone in Iowa

Iowa permits telehealth prescribing of pioglitazone with no state-specific restrictions beyond standard prescribing requirements. A provider licensed in Iowa can evaluate a patient via synchronous video or audio-visual encounter and prescribe pioglitazone if clinically appropriate.

Iowa's telehealth parity law (Iowa Code § 514C.34) requires commercial insurers to cover telehealth services at the same reimbursement rate as in-person visits, which means the consultation itself should be covered. The Iowa Board of Medicine requires that the prescriber establish a valid provider-patient relationship before issuing the prescription, but Iowa accepts real-time telemedicine encounters as sufficient to establish that relationship.

For patients in rural Iowa counties (and roughly 80 of Iowa's 99 counties qualify as rural by HRSA designation), telehealth access to an endocrinologist or hepatologist who is comfortable prescribing pioglitazone for MASLD can be the difference between receiving evidence-based care and not. The nearest academic hepatology center for many Iowans is the University of Iowa Hospitals and Clinics in Iowa City, which may be a three-hour drive from northwest Iowa.

Telehealth platforms operating nationally, including HealthRX, can connect Iowa patients with providers who prescribe pioglitazone for both its FDA-approved diabetes indication and its off-label MASLD use. The prescription is then filled at the patient's local Iowa pharmacy or through mail-order.

Discount Programs and Savings Strategies for Iowa Patients

Several pathways can reduce pioglitazone costs below the $15 Iowa average. Generic discount programs at Walmart ($4 list), Hy-Vee ($4 generics program), and Costco member pricing often place pioglitazone at or below $10 for a 30-day supply.

Pharmacy discount platforms (GoodRx, RxSaver, SingleCare) aggregate negotiated prices across Iowa pharmacy networks. These coupons are free to use and do not require insurance. In Iowa ZIP codes surveyed, GoodRx prices for pioglitazone 30 mg #30 tablets ranged from $4.50 to $18 depending on the pharmacy, with Costco and Walmart consistently at the low end 4.

Takeda, the original manufacturer of Actos, does not currently offer a branded savings card for pioglitazone, as the brand has been off-patent for over a decade. Generic manufacturers similarly do not run patient assistance programs for pioglitazone because the drug is already inexpensive. This is a case where the market has done what patient assistance programs exist to do: make the drug affordable.

For uninsured Iowa patients, 340B-eligible health centers can dispense pioglitazone at reduced cost. Iowa has over 20 federally qualified health centers (FQHCs) participating in the 340B Drug Pricing Program, and several operate their own in-house pharmacies. Patients meeting income eligibility (generally at or below 200% of the federal poverty level) can access 340B pricing, which for a generic drug like pioglitazone may bring the cost to $0 to $5.

The Iowa Prescription Drug Corporation, a state-administered program, provides limited assistance to qualifying residents, though its formulary and eligibility criteria change annually. Checking with the Iowa Department of Health and Human Services for current program details is worthwhile for patients exploring every option.

Safety Considerations That Affect Cost Decisions

Pioglitazone's low price does not eliminate the need for clinical monitoring, and monitoring costs should factor into the total expense of therapy. The FDA label requires prescribers to check liver enzymes (ALT) before initiation and periodically thereafter [5]. A basic metabolic panel plus liver function tests runs $20 to $50 at most Iowa labs without insurance.

The boxed warning for pioglitazone concerns congestive heart failure. Thiazolidinediones cause dose-dependent fluid retention that can precipitate or worsen heart failure in susceptible patients. The PROactive study reported heart failure hospitalizations in 5.7% of pioglitazone patients versus 4.1% on placebo (P=0.007), though all-cause mortality did not differ [6].

Weight gain is the other cost-adjacent concern. Pioglitazone causes a mean weight gain of 2 to 4 kg over the first year, driven primarily by fluid retention and adipocyte differentiation. In PIVENS, the mean weight gain was 4.7 kg over 96 weeks [3]. For patients considering pioglitazone for MASLD while also trying to manage weight, this tradeoff requires explicit discussion.

The American Association of Clinical Endocrinology (AACE) 2023 guidelines position pioglitazone as a reasonable option for patients with type 2 diabetes and MASLD who do not have heart failure (NYHA Class III or IV), noting that the metabolic benefits in the liver may outweigh the weight gain risk when hepatic fibrosis is present.

Bone density loss is a third consideration, particularly relevant for postmenopausal women. The IRIS trial (N=3,876) documented increased fracture rates with pioglitazone in insulin-resistant patients without diabetes. Iowa patients on pioglitazone long-term should discuss baseline and periodic DEXA screening with their provider, adding roughly $150 to $300 per scan (often covered by insurance every two years for women over 65 or those with risk factors).

How Pioglitazone Compares to Other Diabetes Drugs on Cost in Iowa

Pioglitazone's $15 per month price point in Iowa places it in the same tier as metformin ($4 to $10) and glipizide ($4 to $12). All three are generic, oral, once-daily medications available at every pharmacy in the state.

The cost gap widens dramatically with newer drug classes. In Iowa, empagliflozin (Jardiance) averages $540 per month without insurance. Sitagliptin (Januvia) runs roughly $450. Injectable semaglutide (Ozempic) exceeds $900 per month, and tirzepatide (Mounjaro) is priced similarly 7. These branded agents offer benefits that pioglitazone does not (GLP-1 agonists produce significant weight loss; SGLT2 inhibitors reduce heart failure hospitalizations in patients with established HFrEF), but for the specific clinical niche of insulin sensitization and MASLD treatment, pioglitazone delivers evidence-backed outcomes at 2% of the cost.

The ADA's cost-conscious prescribing algorithm recommends starting with metformin, then adding a second agent based on patient-specific factors including cost constraints. For an uninsured Iowa patient with type 2 diabetes and fatty liver disease, pioglitazone at $15 per month may be the most rational second-line choice purely on a cost-effectiveness basis.

A 2022 cost-effectiveness analysis published in Diabetes Care estimated the incremental cost-effectiveness ratio (ICER) of pioglitazone versus placebo at approximately $2,200 per quality-adjusted life year (QALY) gained, well below the $50,000-per-QALY threshold commonly used in U.S. health economic evaluations [8].